Using arterial embolization to treat bone metastases
Embolizzazione Arteriosa Per il Trattamento Delle Metastasi Ossee: Studio Osservazionale Prospettico
Istituto Ortopedico Rizzoli · NCT06189079
This study is testing whether a minimally invasive treatment called arterial embolization can help reduce pain and improve outcomes for patients with bone metastases.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Istituto Ortopedico Rizzoli (other) |
| Locations | 1 site (Bologna, Emilia-Romagna) |
| Trial ID | NCT06189079 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the use of arterial embolization as a minimally invasive treatment for patients with bone metastases. It aims to evaluate the effectiveness of this method in reducing pain, controlling local disease, and minimizing peri-operative bleeding. The study will include patients who are candidates for embolization therapy and will monitor their outcomes over time. The approach is designed to provide insights into the benefits and risks associated with this treatment modality.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with single or oligometastatic bone lesions who have a life expectancy of more than three months.
Not a fit: Patients with severe functional status impairment, life expectancy of less than three months, or specific contraindications such as hypovascular metastasis may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve pain management and quality of life for patients with bone metastases.
How similar studies have performed: Previous studies have shown promising results with arterial embolization for similar conditions, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients of either sex of age or older who are candidates for embolization therapy * Life expectancy \> 3 months * Single metastatic or oligometastatic. * Plurimetastatic if a particular site is causing painful symptoms or at risk for pathologic rupture Exclusion Criteria: * Patients with life expectancy \<3 months or severe functional status impairment (ASA 4) * Patients with hypovascular metastasis documented by angiography or MRI perfusion study with MDC. * Patients with coagulation deficiency or plateletopenic patients. * Patients with documented active infection.
Where this trial is running
Bologna, Emilia-Romagna
- Istituto Ortopedico Rizzoli — Bologna, Emilia-Romagna, Italy (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Bone Metastases, Arterial embolization